Advanced search×

Cutaneous and systemic plasmacytosis in an Asian male born in the North American continent: A controversial entity potentially related to multicentric Castleman disease

J Cutan Pathol Ahead of Print:697 (2010) PMID 19614735

Cutaneous and systemic plasmacytosis is a rare condition primarily affecting middle-aged individuals of Japanese descent and has principally been reported in cases originating from Asia. Its relationship, if any, to Castleman disease, is controversial. The authors report a case of cutaneous and systemic plasmacytosis involving a 36-year-old man of Chinese ancestry born in North America. The biopsy of an involved lymph node revealed changes resembling Castleman disease. Significantly, this case to our knowledge represents the first case of cutaneous and systemic plasmacytosis presenting in a patient of Chinese ancestry born on the North American mainland. Shadel BN, Frater JL, Gapp JDG, Hurley MY. Cutaneous and systemic plasmacytosis in an Asian male born in the North American continent: A controversial entity potentially related to multicentric Castleman disease.

DOI: 10.1111/j.1600-0560.2009.01372.x
Version: za2963e q8zac q8zb5 q8zcf q8zd3 q8ze9 q8zfc q8zge

Similar articles you may find interesting…

  1. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].

    Zhonghua Nei Ke Za Zhi 49(8):649-52 (2010) PMID 20979781

    To evaluate the influence of highly active antiretroviral therapy (HAART)on bone mineral density(BMD) of human immunodeficiency virus (HIV) infected patients and correlating clinical factors. The clinical data from 2007 to 2008 were analyzed, including 50 patients treated with HAART (named treated g...
  2. [Effects of Hengyan medicinal recipe on the regulation of immunity in patients with severe sepsis: a prospective clinical trial].

    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 23(2):77-80 (2011) PMID 21315002

    To observe the role of Hengyan medicinal recipe on the regulation of immunity in patients with severe sepsis.
  3. [A multicenter study of the effectiveness of interferon alpha-1b (Hapgen) in treating HBeAg positive chronic hepatitis B patients].

    Zhonghua Gan Zang Bing Za Zhi 19(1):25-8 (2011) PMID 21272454

    To compare the efficacy and safety of interferon a-1b and interferon a-1b combined with lamivudine in the treatment of HBeAg positive chronic hepatitis B (CHB), to analyze the impact of variable factors on the efficacy, and to investigate the individualized anti-viral regimen for CHB...